We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.23%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$852M
AUM Growth
+$402M
Cap. Flow
+$256M
Cap. Flow %
30.02%
Top 10 Hldgs %
54.49%
Holding
73
New
24
Increased
20
Reduced
15
Closed
11
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$48.3M
2
AZN icon
AstraZeneca
AZN
+$41.9M
3
GSK icon
GSK
GSK
+$32.4M
4
UTHR icon
United Therapeutics
UTHR
+$28.6M
5
AMRN icon
Amarin Corp
AMRN
+$25.5M

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.5M
2
OSUR icon
OraSure Technologies
OSUR
+$11.4M
3
HSKA
Heska Corp
HSKA
+$10.3M
4
LAB icon
Standard BioTools
LAB
+$9.68M
5
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.33%
3 Financials 0.05%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DXCM icon
51
DexCom
DXCM
$32.5B
$914K 0.11%
+9,892
New +$883K
2020 Q4
0 quarters
TARA icon
52
Protara Therapeutics
TARA
$137M
$879K 0.1%
36,310
– –
2020 Q1
3 quarters
IQV icon
53
IQVIA
IQV
$43.9B
$732K 0.09%
+4,085
New +$688K
2020 Q4
0 quarters
A icon
54
Agilent Technologies
A
$48.8B
$590K 0.07%
+4,977
New +$551K
2020 Q4
0 quarters
GOCO icon
55
DELISTED
GoHealth
GOCO
$405K 0.05%
1,979
+1,104
+126% +$205K
2020 Q3
1 quarter
KALV icon
56
DELISTED
KalVista Pharmaceuticals
KALV
$359K 0.04%
18,925
-88,375
-82% -$1.52M
2020 Q2
2 quarters
LCI
57
CALL
DELISTED
Lannett Company, Inc.
LCI
$354K 0.04%
15,975
-14,650
-48% -$383K
2020 Q3
1 quarter
ZYME icon
58
Zymeworks
ZYME
$1.8B
$255K 0.03%
+5,405
New +$251K
2020 Q4
0 quarters
MRUS icon
59
DELISTED
Merus
MRUS
$253K 0.03%
+14,445
New +$213K
2020 Q4
0 quarters
APLS icon
60
DELISTED
Apellis Pharmaceuticals
APLS
$218K 0.03%
3,816
-77,451
-95% -$3.28M
2018 Q2
10 quarters
CYTK icon
61
CALL
Cytokinetics
CYTK
$8.61B
$208K 0.02%
+10,000
New +$183K
2020 Q4
0 quarters
CYH icon
62
Community Health Systems
CYH
$406M
$95.1K 0.01%
+12,805
New +$90.6K
2020 Q4
0 quarters
CLDX icon
63
Celldex Therapeutics
CLDX
$2.16B
– –
-150,494
Closed -$2.23M –
LAB icon
64
Standard BioTools
LAB
$247M
– –
-1,302,353
Closed -$9.68M –
LQDA icon
65
Liquidia Corp
LQDA
$3.07B
– –
-182,751
Closed -$899K –
MRSN icon
66
DELISTED
Mersana Therapeutics
MRSN
– –
-5,600
Closed -$2.61M –
OSUR icon
67
OraSure Technologies
OSUR
$249M
– –
-940,412
Closed -$11.4M –
SCPH icon
68
DELISTED
scPharmaceuticals
SCPH
– –
-65,605
Closed -$489K –
SLDB icon
69
Solid Biosciences
SLDB
$593M
– –
-20,468
Closed -$623K –
VTRS icon
70
Viatris
VTRS
$21.4B
– –
-324,951
Closed -$4.82M –
MODN icon
71
DELISTED
MODEL N, INC.
MODN
– –
-188,967
Closed -$6.67M –
TLGT
72
DELISTED
Teligent, Inc
TLGT
– –
-305,423
Closed -$220K –
MNTA
73
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-98,501
Closed -$5.17M –
1 2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Eversept Partners held 73 positions worth $852M, up 89% from $450M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Eversept Partners deployed $256M of net new capital in Q4 2020, opening 24 new positions and adding to 20 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $18.5M trimmed.

  • Eversept Partners's largest Q4 2020 buy was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.
  • Eversept Partners added most to AstraZeneca in Q4 2020, an estimated $41.9M increase.
  • Eversept Partners's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $18.5M.
  • Eversept Partners fully exited OraSure Technologies in Q4 2020, selling an estimated $11.4M.
  • Eversept Partners's ten largest holdings make up 54% of its $852M portfolio in Q4 2020.
  • Eversept Partners opened 24 new positions and closed 11 in Q4 2020.
  • Eversept Partners's portfolio value rose 89% quarter-over-quarter to $852M.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.